Imaging of cardiac amyloidosis using dynamic 18F-FPYBF-2 positron emission tomography

IF 2.5 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Annals of Nuclear Medicine Pub Date : 2024-12-20 DOI:10.1007/s12149-024-02010-7

Chio Okuyama, Yasutaka Inuzuka, Yuzo Takeuchi, Kohsuke Asagoe, Shinya Kagawa, Miki Ito, Kuninori Kusano, Yoshiharu Fujita, Hiroyuki Watanabe, Masahiro Ono, Tatsuya Higashi

{"title":"Imaging of cardiac amyloidosis using dynamic 18F-FPYBF-2 positron emission tomography","authors":"Chio Okuyama, Yasutaka Inuzuka, Yuzo Takeuchi, Kohsuke Asagoe, Shinya Kagawa, Miki Ito, Kuninori Kusano, Yoshiharu Fujita, Hiroyuki Watanabe, Masahiro Ono, Tatsuya Higashi","doi":"10.1007/s12149-024-02010-7","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>This study aimed to evaluate the diagnostic ability of 5-(5-(2-(2-(2-<sup>18</sup>F-fluoroethoxy) ethoxy) ethoxy) benzofuran-2-yl)-N-methylpyridin-2-amine (<sup>18</sup>F-FPYBF-2) dynamic PET for patients with cardiac amyloidosis (CA).</p><h3>Methods</h3><p>The subjects were patients diagnosed with proven amyloidosis (<i>n</i> = 16) including transthyretin cardiac amyloidosis (ATTR-CA) (<i>n</i> = 7) and light chain amyloidosis (AL amyloidosis) (<i>n</i> = 9), of which 4 and 5 with (AL-CA) and without (AL-nCA) cardiac involvement, and 4 control subjects suffering from some symptoms of cardiac failure without amyloidosis (CTL). Thirty minutes dynamic <sup>18</sup>F-FPYBF-2 PET/CT was performed to evaluate the time activity curve and the retention index (mRI) as the ratio of the myocardial SUV at 15 to 5 min. The results of bone scan were also evaluated except for 2 AL-nCA cases.</p><h3>Results</h3><p>Diffuse <sup>18</sup>F-FPYBF-2 distribution in the myocardium was observed within a few minutes in all cases. The accumulation was still seen at 30 min after injection in all the CA cases, while it showed rapid clearance in CTL and AL-nCA cases. The values mRI of the ATTR-CA and AL-CA were significantly higher than CTL and AL-nCA cases, and AL-CA showed higher value than ATTR-CA (p < 0.05), while the positive results of bone scan were observed in all ATTR-CA cases, and in one case of AL-CA.</p><h3>Conclusions</h3><p><sup>18</sup>F-FPYBF-2 PET could be a useful tool to evaluate cardiac involvement of amyloidosis and can visualize AL-CA regardless of the results of bone scan.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 4","pages":"398 - 403"},"PeriodicalIF":2.5000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12149-024-02010-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

This study aimed to evaluate the diagnostic ability of 5-(5-(2-(2-(2-¹⁸F-fluoroethoxy) ethoxy) ethoxy) benzofuran-2-yl)-N-methylpyridin-2-amine (¹⁸F-FPYBF-2) dynamic PET for patients with cardiac amyloidosis (CA).

Methods

The subjects were patients diagnosed with proven amyloidosis (n = 16) including transthyretin cardiac amyloidosis (ATTR-CA) (n = 7) and light chain amyloidosis (AL amyloidosis) (n = 9), of which 4 and 5 with (AL-CA) and without (AL-nCA) cardiac involvement, and 4 control subjects suffering from some symptoms of cardiac failure without amyloidosis (CTL). Thirty minutes dynamic ¹⁸F-FPYBF-2 PET/CT was performed to evaluate the time activity curve and the retention index (mRI) as the ratio of the myocardial SUV at 15 to 5 min. The results of bone scan were also evaluated except for 2 AL-nCA cases.

Results

Diffuse ¹⁸F-FPYBF-2 distribution in the myocardium was observed within a few minutes in all cases. The accumulation was still seen at 30 min after injection in all the CA cases, while it showed rapid clearance in CTL and AL-nCA cases. The values mRI of the ATTR-CA and AL-CA were significantly higher than CTL and AL-nCA cases, and AL-CA showed higher value than ATTR-CA (p < 0.05), while the positive results of bone scan were observed in all ATTR-CA cases, and in one case of AL-CA.

Conclusions

¹⁸F-FPYBF-2 PET could be a useful tool to evaluate cardiac involvement of amyloidosis and can visualize AL-CA regardless of the results of bone scan.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

使用动态 18F-FPYBF-2 正电子发射断层扫描对心脏淀粉样变性进行成像。

目的：评价5-（5-（2-（2-（2- 18f -氟乙氧基）乙氧基）乙氧基）苯并呋喃-2-基）- n-甲基吡啶-2-胺（18F-FPYBF-2）动态PET对心脏淀粉样变性（CA）患者的诊断能力。方法：研究对象为经甲状腺素性心脏淀粉样变性（atr - ca）（n = 7）和轻链淀粉样变性（AL淀粉样变性）（n = 9）确诊的淀粉样变性患者（n = 16），其中伴有（AL- ca）和不伴有（AL- nca）心脏受累的患者4名和5名，对照组4名有部分心力衰竭症状但无淀粉样变性（CTL）。30分钟动态18F-FPYBF-2 PET/CT评价时间活度曲线和保留指数（mRI）作为15 ~ 5分钟心肌SUV的比值。除2例AL-nCA外，还评价骨扫描结果。结果：所有病例心肌弥漫性18F-FPYBF-2分布均在数分钟内出现。在所有CA病例中，注射后30min仍可见积聚，而在CTL和AL-nCA病例中，积聚迅速清除。atr - ca和AL-CA的mRI值明显高于CTL和AL-nCA， AL-CA的价值高于atr - ca (p)。结论：18F-FPYBF-2 PET可作为评估淀粉样变性心脏累及的有效工具，无论骨扫描结果如何，都能显示AL-CA。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Annals of Nuclear Medicine 医学-核医学

CiteScore

4.90

自引率

7.70%

发文量

111

审稿时长

4-8 weeks

期刊介绍： Annals of Nuclear Medicine is an official journal of the Japanese Society of Nuclear Medicine. It develops the appropriate application of radioactive substances and stable nuclides in the field of medicine. The journal promotes the exchange of ideas and information and research in nuclear medicine and includes the medical application of radionuclides and related subjects. It presents original articles, short communications, reviews and letters to the editor.